 Interleukin-3
"Interleukin-3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells.
| Descriptor ID |
D007377
|
| MeSH Number(s) |
D12.644.276.374.410.240.400 D12.644.276.374.465.032 D12.776.395.240.400 D12.776.467.374.410.240.400 D12.776.467.374.465.032 D23.529.374.410.240.400 D23.529.374.465.169
|
| Concept/Terms |
Interleukin-3- Interleukin-3
- Interleukin 3
- IL-3
- Mast-Cell Colony-Stimulating Factor
- Multipotential Colony-Stimulating Factor
- Multipotential Colony Stimulating Factor
- Erythrocyte Burst-Promoting Factor
- Erythrocyte Burst Promoting Factor
- Burst-Promoting Factor, Erythrocyte
- Burst Promoting Factor, Erythrocyte
- Colony-Stimulating Factor 2 Alpha
- Colony-Stimulating Factor, Mast-Cell
- Colony Stimulating Factor, Mast Cell
- Colony-Stimulating Factor, Multipotential
- Colony Stimulating Factor, Multipotential
- Eosinophil-Mast Cell Growth-Factor
- Eosinophil Mast Cell Growth Factor
- Hematopoietin-2
- Hematopoietin 2
- P-Cell Stimulating Factor
- P Cell Stimulating Factor
|
Below are MeSH descriptors whose meaning is more general than "Interleukin-3".
Below are MeSH descriptors whose meaning is more specific than "Interleukin-3".
This graph shows the total number of publications written about "Interleukin-3" by people in this website by year, and whether "Interleukin-3" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2014 | 0 | 1 | 1 | | 2022 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Interleukin-3" by people in Profiles.
-
Li Y, Qi X, Zhao D, Urban JF, Huang H. IL-3 Expands Pre-Basophil and Mast Cell Progenitors by Upregulating the IL-3 Receptor Expression. Cell Immunol. 2022 04; 374:104498.
-
Saurabh K, Scherzer MT, Shah PP, Mims AS, Lockwood WW, Kraft AS, Beverly LJ. The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget. 2014 Sep 30; 5(18):8503-14.
-
Frankel AE, Woo JH, Ahn C, Pemmaraju N, Medeiros BC, Carraway HE, Frankfurt O, Forman SJ, Yang XA, Konopleva M, Garnache-Ottou F, Angelot-Delettre F, Brooks C, Szarek M, Rowinsky E. Activity of SL-401, a targeted therapy directed to interleukin-3 receptor, in blastic plasmacytoid dendritic cell neoplasm patients. Blood. 2014 Jul 17; 124(3):385-92.
-
Hermanrud CE, Pathiraja V, Matar A, Duran-Struuck R, Crepeau RL, Srinivasan S, Sachs DH, Huang CA, Wang Z. Expression and purification of non-N-glycosylated porcine interleukin 3 in yeast Pichia pastoris. Protein Expr Purif. 2012 Mar; 82(1):70-4.
-
Ohmori K, Luo Y, Jia Y, Nishida J, Wang Z, Bunting KD, Wang D, Huang H. IL-3 induces basophil expansion in vivo by directing granulocyte-monocyte progenitors to differentiate into basophil lineage-restricted progenitors in the bone marrow and by increasing the number of basophil/mast cell progenitors in the spleen. J Immunol. 2009 Mar 01; 182(5):2835-41.
-
Horita H, Frankel AE, Thorburn A. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death. Leukemia. 2008 Mar; 22(3):652-5.
-
Jiang X, Zhao Y, Smith C, Gasparetto M, Turhan A, Eaves A, Eaves C. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia. 2007 May; 21(5):926-35.
-
Liu TF, Urieto JO, Moore JE, Miller MS, Lowe AC, Thorburn A, Frankel AE. Diphtheria toxin fused to variant interleukin-3 provides enhanced binding to the interleukin-3 receptor and more potent leukemia cell cytotoxicity. Exp Hematol. 2004 Mar; 32(3):277-81.
-
Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, Lilly M. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67.
-
Lima B, Gleit ZL, Cameron AM, Germana S, Murphy MC, Consorti R, Chang Q, Down JD, LeGuern C, Sachs DH, Huang CA. Engraftment of quiescent progenitors and conversion to full chimerism after nonmyelosuppressive conditioning and hematopoietic cell transplantation in miniature swine. Biol Blood Marrow Transplant. 2003 Sep; 9(9):571-82.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|